Medtronic Plc agreed to buy the shares it doesn’t already own in Mazor Robotics Ltd. in a deal valuing the company at $1.6 billion, as the medical equipment giant expands its leadership in the market for spinal surgery.
Medtronic agreed to pay $58.50 per American depositary share, the companies said in a statement Thursday. That’s an 11 percent premium over the closing price in New York, but far below a peak of almost $75 reached in March. Excluding Medtronic’s existing investment and Mazor’s cash on hand, it will pay $1.3 billion. Medtronic previously held an 11 percent stake, according to Bloomberg data.
Click here to read this article in its entirety.